Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers
Home › TN › CLEVELAND › ELITE PAIN CONSULTANTS, PLLC

ELITE PAIN CONSULTANTS, PLLC

NPI: 1497267173 · CLEVELAND, TN 37311 · Interventional Pain Medicine Physician

$1.55M
Total Medicaid Paid
87,664
Total Claims
71,723
Beneficiaries
69
Codes Billed
2018-06
First Month
2023-10
Last Month

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 2,519 $57K
2019 17,162 $481K
2020 15,672 $399K
2021 24,338 $318K
2022 25,803 $267K
2023 2,170 $24K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
99214 39,382 33,686 $916K
J3300 Injection, triamcinolone acetonide, preservative free, 1 mg 1,879 761 $190K
99204 1,647 1,453 $83K
99213 4,262 3,836 $59K
64493 1,006 701 $58K
80307 9,650 8,158 $31K
64494 995 696 $28K
64635 207 140 $26K
80305 3,897 3,427 $25K
96132 2,359 1,691 $21K
96130 2,496 1,749 $17K
27096 106 79 $16K
81025 3,359 2,845 $15K
64636 290 139 $12K
62323 80 72 $6K
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed 1,373 1,001 $5K
96138 2,530 1,763 $4K
72114 220 199 $4K
G3002 Chronic pain management and treatment, monthly bundle including, diagnosis; assessment and monitoring; administration of a validated pain rating scale or tool; the development, implementation, revision, and/or maintenance of a person-centered care plan that includes strengths, goals, clinical needs, and desired outcomes; overall treatment management; facilitation and coordination of any necessary behavioral health treatment; medication management; pain and health literacy counseling; any necessary chronic pain related crisis care; and ongoing communication and care coordination between relevant practitioners furnishing care, e.g. physical therapy and occupational therapy, complementary and integrative approaches, and community-based care, as appropriate. required initial face-to-face visit at least 30 minutes provided by a physician or other qualified health professional; first 30 minutes personally provided by physician or other qualified health care professional, per calendar month. (when using g3002, 30 minutes must be met or exceeded.) 369 269 $4K
20611 116 70 $3K
G0396 Alcohol and/or substance (other than tobacco) misuse structured assessment (e.g., audit, dast), and brief intervention 15 to 30 minutes 2,423 1,742 $3K
64450 51 33 $3K
20553 83 64 $2K
64495 184 141 $1K
82962 988 686 $1K
J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg 451 361 $1K
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed 202 138 $1K
99203 30 29 $1K
G0444 Annual depression screening, 5 to 15 minutes 718 513 $939.74
76942 70 51 $887.81
83970 131 112 $452.52
99211 45 40 $399.02
99421 64 59 $363.75
82306 131 112 $324.67
82670 131 112 $305.85
72170 35 31 $301.90
84403 131 112 $282.94
72100 33 28 $282.29
73560 42 25 $280.04
82627 131 112 $243.73
84144 129 111 $219.34
84146 131 112 $212.58
J1100 Injection, dexamethasone sodium phosphate, 1 mg 650 491 $208.64
83001 131 112 $203.89
83002 132 112 $203.12
84481 131 112 $185.86
83003 131 112 $182.96
82533 131 112 $178.78
83735 245 207 $172.43
84443 130 111 $169.20
82607 131 112 $165.18
82746 131 112 $161.26
99406 35 26 $153.89
82977 242 206 $118.28
83615 246 207 $104.87
86431 244 206 $98.42
84439 131 112 $90.73
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 53 36 $89.55
84550 244 207 $78.26
80069 244 207 $71.86
36415 262 222 $65.92
86140 131 112 $56.74
82728 241 205 $45.08
80053 97 81 $39.52
83550 242 206 $28.98
83540 245 207 $21.39
80076 245 207 $6.22
84436 131 112 $6.18
84100 131 112 $3.94